Photo: Myeloma Research
May 27, 2023, 16:54
Is There An ‘Optimal’ Carfilzomib Dose For Relapsed Or Refractory MM?- Blood Cancer Today
A new study suggests there is an “optimal” dose of carfilzomib for patients with relapsed or refractory multiple myeloma (MM).
Xiang Zhou, MD, of the University Hospital of Würzburg in Germany; Andrej Besse, PhD, of Cantonal Hospital St. Gallen in Switzerland; and colleagues conducted the research because “optimal carfilzomib dosing is a matter of debate.”
They used 103 pairs of peripheral blood mononuclear cells from patients with relapsed or refractory MM to analyze the inhibition profiles of proteolytic proteasome subunits β5, β2, and β1 in response to carfilzomib. They compared low-dose carfilzomib (20 mg/m2 or 27 mg/m2) with high-dose carfilzomib (≥36 mg/m2) in the samples.
Sourse: Blood Cancer Today
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 18:02
Dec 22, 2024, 17:54
Dec 22, 2024, 17:51
Dec 22, 2024, 17:47
Dec 22, 2024, 17:44
Dec 22, 2024, 17:39
Dec 22, 2024, 17:36
Dec 22, 2024, 17:32
Dec 22, 2024, 17:18